Table 1.
Echocardiographic parameters after vehicle or sorafenib treatment
| HR | LVIDd | LVIDs | FS | LVd vol | LVs vol | IVSd | PWd | LV mass | |
|---|---|---|---|---|---|---|---|---|---|
|
Vehicle (5)
Day 0 |
674 ± 9 | 2.6 ± 0.1 | 1.1 ± 0 | 58 ± 2 | 25 ± 2 | 3 ± 0 | 0.9 ± 0 | 1.0 ± 0 | 82 ± 1 |
| Day 14 | 687 ± 8 | 2.8 ± 0.1 | 1.2 ± 0.1 | 57 ± 1 | 29 ± 2 | 3 ± 0 | 1.0 ± 0.1 | 1.0 ± 0 | 85 ± 5 |
|
Sorafenib (5)
Day 0 |
648 ± 17 | 2.7 ± 0.1 | 1.1 ± 0.1 | 56 ± 1 | 26 ± 2 | 3 ± 1 | 1.0 ± 0 | 0.9 ± 0 | 76 ± 4 |
| Day 14 | 694 ± 15 | 2.7 ± 0.1 | 1.3 ± 0.1 | 50 ± 2* | 28 ± 2 | 5 ± 0 | 1.0 ± 0 | 0.9 ± 0 | 88 ± 3a |
Echocardiography was performed on unanaesthetized mice. Values represent mean ± SEM. Two‐tailed t‐tests compared Days 0 and 14 weights within vehicle and sorafenib‐treated groups.
a
P < 0.05 versus Dox + vehicle.
FS, fractional shortening (%); HR, heart rate (beats.min‐1); IVSd, interventricular septal thickness, diastole (mm); LVd vol, left ventricular diastolic volume (mL); LVs vol, left ventricular systolic volume (mL); LVIDd, left ventricular internal diameter, diastole (cm); LVIDs, left ventricular internal diameter, systole (cm); LVm, LV mass, calculated; PWd, posterior wall, diastole (mm).